Form 4: Rapport Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan

David Bredt, Chief Scientific Officer of Rapport Therapeutics, sold 8,500 shares of common stock at an average price of $10.8477 under a pre-arranged Rule 10b5-1 trading plan.

Summary

• David Bredt, the Chief Scientific Officer of Rapport Therapeutics, sold 8,500 shares of the company's common stock on March 14, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024.
• The shares were sold at prices ranging from $10.42 to $11.31, with a weighted average price of $10.8477.
• Following the transaction, Bredt directly owns 469,142 shares of Rapport Therapeutics.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, mitigating concerns about trading on non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative than discretionary trades.

Stakeholder Impact

• The sale of shares by a high-ranking officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates